Short Communication Effects of short chain fatty acid (SCFA) supplementation on performance and egg characteristics of old breeder hens

A study was conducted to determine the effect of supplementing the diet of breeder hens with a short-chain fatty acid (SCFA) premix, containing 509 g fatty acid salts/kg of which 285 g were calcium butyrate, on their eggshell characteristics and the hatching percentage of the eggs. One thousand six hundred 66-week old White Bovans laying breeder hens were used in this experiment. They were housed in eight identical pens, each containing 200 birds, and four pens were used per treatment. The SCFA premix was included at 1000 mg/kg in the treatment diet, and fed for a period of nine weeks. Responses were compared with an unsupplemented treatment. Supplementation started when the hens were 66 weeks old. From day 75 eggs were collected for the next seven weeks and the occurrence of cracked, dirty and misshapen eggs was recorded, and the hatching percentage of the eggs was determined. Eggshell strength was lower in eggs from the control (1.76 ± 0.05) than from the treatment group (2.07 ± 0.03). The percentage of eggs produced by the control group (68.6 ± 0.08) was significantly lower than that by the supplemented group (71.5 ± 0.15). Percentage of dirty, cracked and misshapen eggs, and the hatchability percentage of the control group (1.15 ± 0.03, 3.44 ± 0.05, 6.27 ± 0.03 and 88.93 ± 0.06, respectively) were also significantly lower than in the group receiving SCFA (0.47 ± 0.03, 2.21 ± 0.03, 3.81 ± 0.03 and 93.36 ± 0.05, respectively). It was concluded that dietary supplementation of SCFA to layer breeder hens from 66 weeks of age onwards improved eggshell strength, reduced the percentage of dirty, cracked and misshapen eggs and increased the hatching percentage of the eggs. The positive responses were suggested to be largely due to the butyrate in the SCFA. Keywords: Butyrate; SCFA; eggshell quality; hatching characteristics South African Journal of Animal Science Vol. 37 (3) 2007: pp.158-16

A prospective study of peripheral lymphadenopathy in childhood

WOS: A1997WZ36700015PubMed ID: 914318

Recombinant human erythropoietin trial in thalassemia intermedia

WOS: A1996WB43100005PubMed ID: 9009557It has been shown that high doses of human recombinant erythropoietin (r epo) increase haemoglobin levels by augmentation of F-cells, and Hb-F production in animal models and in human trials. In this study, r epo was used in patients with beta thalassemia intermedia. Our purpose was to improve haemoglobin levels by at least 2 g and maintain an average level between 10 and 12 g/dl. Ten patients aged 6-29 years (mean 14 +/- 7.6 years) with thalassemia intermedia were treated with r epo, It was given subcutaneously in rising doses from 500 to 1000 U/kg three times weekly for 3 months. During r epo therapy eight cases (80 per cent) showed an increase in haemoglobin, haematocrit, and reticulocyte levels, and an increase of at least 2 g of haemoglobin was obtained, Blood transfusion was not needed during the study except in one case, Five cases (50 per cent) improved life quality with therapy, Hb levels of all patients returned to baseline values over 1 or 2 months after r epo was discontinued. There was no significant change in absolute Hb-F, F-cells, and ferritin levels during treatment. Generally, the drug was well tolerated. No patient had hypertension, Recombinant erythropoietin seems to be an effective treatment for anaemia of beta-thalassemia intermedia, but longer term randomized trials are needed especially in patients with beta thalassemia major

Hematopoietic Stem Cell Transplantation In Pediatric Langerhans Cell Histiocytosis: Experience of Ege University From Turkey

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation -- MAR 22-25, 2015 -- Istanbul, TURKEYWOS: 000351632903206European Soc Blood & Marrow Transplanta